©The Author(s) 2025.
World J Gastroenterol. Sep 28, 2025; 31(36): 111557
Published online Sep 28, 2025. doi: 10.3748/wjg.v31.i36.111557
Published online Sep 28, 2025. doi: 10.3748/wjg.v31.i36.111557
Figure 5 Recombinant peroxiredoxin 1 induces pyroptosis of RKO and SW480 cells.
Representative images of pyroptosis induced by recombinant peroxiredoxin 1 (rPrdx1) without or with NLRP3 inflammasome inhibitor (MCC950) and GSDMD inhibitor (Ac-FLTD-CMK) treatment (n = 3 per group), scale bar: 20 μm (× 10000). rPrdx1: 20 μM for 24 hours. MCC950: 10 μM for 24 hours. Ac-FLTD-CMK: 10 μM for 24 hours. Prdx1: Peroxiredoxin 1.
- Citation: He Y, Liu J, Zhou N, Xie LX, Jiang YF, Chen CL. Peroxiredoxin 1 inhibits tumorigenesis by activating the NLRP3/GSDMD pathway to induce pyroptosis of colorectal cancer cells. World J Gastroenterol 2025; 31(36): 111557
- URL: https://www.wjgnet.com/1007-9327/full/v31/i36/111557.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i36.111557